Long-term remission from acute myelogenous leukemia after bone marrow transplantation and recovery from acute graft-versus-host reaction and prolonged immunoincompetence.
A 19-yr-old boy has been in continuous complete remission from acute myelogenous leukemia for 3 yr after allogeneic bone marrow transplantation prepared with combination chemotherapy. During the first year post-transplant, however, the patient developed near-fatal graft-versus-host reaction followed by 11 severe viral and bacterial infections. Immune evaluation during this period revealed multiple defects which were not present prior to transplantation, nor present in the transplant donor: diminution of lymphoid tissue, decline of all immunoglobulin subtypes, deletion of secretory immunoglobulin, disappearance of isohemagglutinins, loss of antibody to diptheria and tetanus toxoids, cessation of cutaneous hypersensitivity to mumps antigen, and inhibition of serum opsonizing activity. The patient was also unable to develop normal humoral or cellular reactivity to brucella antigen, keyhole limpet hemocyanin, or dinitrochlorobenzene. This patient's course illustrates the severity and chronicity of immunoincompetence associated with allogeneic marrow grafting, the importance of early detection and rigorous treatment of infectious disease in these patients, and the need for improved immunologic reconstitution in human marrow transplantation. It also indicates that complete recovery from the immune defects is possible, and that long-term remission from acute myelogenous leukemia can be achieved with allogeneic marrow transplantation.
D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D001424:Bacterial Infections / Q000209:etiology; D001787:Blood Group Incompatibility; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002177:Candidiasis / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D006087:Graft vs Host Reaction / Q000628:therapy; D006649:Histocompatibility Antigens; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007153:Immunologic Deficiency Syndromes / Q000209:etiology*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009895:Opsonin Proteins; D013601:T-Lymphocytes / Q000276:immunology; D013866:Thioguanine / Q000627:therapeutic use; D014184:Transplantation, Homologous; D014777:Virus Diseases / Q000209:etiology
D000017:ABO Blood-Group System; D000900:Anti-Bacterial Agents; D000961:Antilymphocyte Serum; D006649:Histocompatibility Antigens; D009607:Nitrosourea Compounds; D009895:Opsonin Proteins; D003561:Cytarabine; D003520:Cyclophosphamide; D013866:Thioguanine